Genzyme pays $22.28 Million settling False Claims whistleblower case on “slurry” in patients

Genzyme, a biotechnology corporation in Cambridge Massachusetts has agreed to pay $22.28 million to resolve a case which alleged false claims were submitted to federal and state health care programs for use of a “slurry” version of its Seprafilm adhesion barrier.¬†

Seprafilm is a thin film intended to reduce adhesions after surgery by forming a bio-resorbable barrier between abdominal tissue and organs. Its FDA approved use is for open abdominal surgery not laproscopic surgery. Uncle Sam alleged that Genzyme ¬†sales reps taught doctors and other staff to use the film in laproscopic surgeries by making a “slurry” consisting of small pieces of the film combined with saline.

The case was originally filed against the company in Florida by a whistleblower who will share in the recovery.

Jeffrey Newman represents whistleblowers.